Researchers say they have achieved enough coherence of the magnetic moment inherent in the defects of miniscule diamond fragments to harness their potential for precise quantum sensors in a material that is biocompatible.
Ziehm Imaging, a developer, manufacturer and supplier of mobile C-arms, will showcase the first motorized mobile C-arm for use in hybrid ORs at the Radiological Society of North America Annual Meeting (RSNA 2013) in Chicago.
Siemens Healthcare will introduce version VA30 of its routine 3-D and advanced reading software syngo.via at the Radiological Society of North America Annual Meeting (RSNA 2013).
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
After cardiac surgery, healthcare-associated infections (HAIs) are common complications associated with increased morbidity, mortality, and use of resources.
Combining genetic data with clinical information to determine the initial dosage of the blood thinner warfarin, used to prevent blood clots in the circulatory system, was no more effective in achieving stable anticoagulation than using only clinical information, according to a National Institutes of Health-funded clinical trial.
Medic Vision Imaging Solutions Ltd. recently signed agreements with three major healthcare purchasing organizations, namely Premier and Health Trust PG, to offer the SafeCT to thousands of their member hospitals and other healthcare providers at pre-negotiated special terms.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Barco, a supplier of diagnostic and visualization systems, will demonstrate a wide array of imaging technologies focused on providing an integrated approach to patient care. Barco will present its latest display systems, networked digital OR solution and interactive patient care products at the Radiological Society of North America Annual Meeting (RSNA 2013) Dec. 1-5 in Chicago.
Vital Images Inc. will participate in the Image Sharing Demonstration (North Building, Hall B, booth 8140) at the annual meeting of the Radiological Society of North America (RSNA), Dec. 1-5 in Chicago.
Etiam Corp. will present the Etiam-Connect along with its Nexus 4.2 update, which features a smoother client interface, at the 2013 annual meeting of the Radiological Society of North America (RSNA).
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
ContextVision will debut four real-time ultrasound image enhancement packages as part of its US PlusView Family at the Radiological Society of North America Annual Meeting (RSNA 2013) in Chicago.
Barco, a supplier of diagnostic systems, presented its MDSC line of network-ready surgical displays.
Millar Inc. and CD Leycom announced the appointment of Millar as the exclusive U.S. distributor of CD Leycom’s clinical Inca in pressure-volume (PV) loop system and disposable clinical PV loop catheters.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
A 320-detector computed tomography (CT) scanner that shows both anatomy within coronary arteries and blood flow can accurately sort out which people need an invasive procedure to identify coronary blockages, according to an international study.
GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) in-house. Optison is a contrast agent that may improve the visualization of the left ventricular border ? an area of the heart that is critical to see in order to assess and diagnose certain heart diseases. As a result of the FDA’s action, GE Healthcare will provide a supply of Optison to the U.S. and European markets from its manufacturing facility in Oslo, Norway, becoming the only contrast media manufacturer to supply its own stock to the United States.
The U.S. Food and Drug Administration (FDA) is warning healthcare professionals of the rare but serious risk of heart attack and death with use of the cardiac nuclear stress test agents Lexiscan (regadenoson) and Adenoscan (adenosine).